Management of Intra-abdominal Metastatic Peripheral Nerve Sheath Tumor
For intra-abdominal metastatic MPNST, systemic chemotherapy with doxorubicin-based regimens (with or without ifosfamide) is the primary treatment, with surgical resection reserved only for resectable metastases when the primary tumor can be controlled, or for symptom palliation. 1
Initial Assessment and Biopsy
Before initiating any treatment for metastatic disease, biopsy confirmation is mandatory 1. This is critical because MPNSTs have overlapping histopathological features with other tumors and require immunohistochemistry for definitive diagnosis 2, 3.
Primary Treatment Strategy
Systemic Chemotherapy
For metastatic (stage IV) MPNST, the treatment approach follows general soft tissue sarcoma guidelines:
First-line options:
- Doxorubicin-based regimens are standard 1, 4, 3
- AIM (doxorubicin/ifosfamide/mesna) is the most active regimen in unselected populations for unresectable/metastatic disease 1
- Single-agent doxorubicin is appropriate for patients who cannot tolerate combination therapy 4
Important caveat: MPNSTs are notoriously chemoresistant with limited treatment options and poor prognosis 5, 6. No targeted therapy has shown objective responses, with disease control rates only 22.9-34.8% across various agents 5.
Role of Surgery in Metastatic Disease
Surgical resection should always be considered if:
- Metastases are resectable AND
- The primary tumor can be controlled 1
Surgery may also be performed for symptom control in unresectable disease 1. However, given the intra-abdominal location, surgery would only be appropriate if it doesn't cause unacceptable morbidity 1.
Radiation Therapy
RT can be combined with systemic therapy for unresectable disease 1. For patients receiving definitive high-dose RT, tissue displacement spacers should be used to protect bowel from high-dose radiation volumes 1.
Second-Line and Beyond
If disease progresses on first-line therapy and the patient remains fit:
Further-line options include:
- Trabectedin - particularly effective in leiomyosarcoma and liposarcoma, with clinical benefit in other histological types 4
- Pazopanib - option for non-adipogenic sarcomas in second-line and beyond 4
- Ifosfamide (if not previously used or if no prior progression) 4
Critical point: For unfit patients or those who have exhausted multiple lines, no further active tumor-directed treatment may be appropriate 4.
Monitoring and Response Assessment
- Follow-up imaging with CT (preferred) or MRI to assess treatment response 1
- If tumors become resectable after systemic therapy, manage as resectable disease with surgical resection 1
- If disease remains unresectable or progresses, transition to palliative/best supportive care 1
Prognosis
The prognosis for metastatic MPNST is dismal, with the vast majority of patients dying within 5 years of diagnosis 6. Intra-abdominal MPNSTs are particularly aggressive 7, 3, and disease recurrence is common even after aggressive treatment 7, 3.